InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF – Get Free Report)’s stock price was down 9.2% on Friday . The company traded as low as $0.26 and last traded at $0.27. Approximately 471,246 shares were traded during mid-day trading, an increase of 4,045% from the average daily volume of 11,369 shares. The stock had previously closed at $0.29.
InMed Pharmaceuticals Stock Down 9.2 %
The stock has a 50-day moving average of $0.27 and a 200 day moving average of $0.26.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain.
Recommended Stories
- Five stocks we like better than InMed Pharmaceuticals
- Investing in Travel Stocks Benefits
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Insider Trades May Not Tell You What You Think
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
